AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of ovarian tissue before HSCT
Number of subjects: 39
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of oocytes before HSCT
Number of subjects: 39
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of ovarian tissue after HSCT
Number of subjects: 39
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of oocytes after HSCT
Number of subjects: 39
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone measurements post HSCT (FSH and AMH)
Number of subjects: 39
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival until January 2021
Number of subjects: 39
Study 34277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive outcomes post HSCT
Number of subjects: 39
Study 34277679 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34277687 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34278044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (750 mg)
Number of subjects: 32
Study 34278044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34278053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy (30 Gy in 5 fractions) for patients with 24 and 30 lesions.
Number of subjects: 5
Study 34278053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy (12 Gy in 2 fractions) for the patient with 50 targets.
Number of subjects: 5
Study 34278053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy treatment plans using volumetric modulated arc therapy.
Number of subjects: 5
Study 34278100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyed sucralfate gel
Number of subjects: 19
Study 34278169 — intervention group
Group type: EXPERIMENTAL
Intervention: selonsertib, firsocostat, or cilofexor, alone or in two-drug combinations
Number of subjects: 392
Study 34278169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 34278595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HLA genotype (DQ2.5/2.5 or DQ2.5/2.2)
Number of subjects: 2943
Study 34278595 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <18 years at diagnosis in index patients
Number of subjects: 2943
Study 34278595 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 41-60 years in relatives
Number of subjects: 2943
Study 34278595 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a sibling of the index patient
Number of subjects: 2943
Study 34278973 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34279212 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34279239 — intervention group
Group type: EXPERIMENTAL
Intervention: Future Patient Telerehabilitation Program B
Number of subjects: 0
Study 34279239 — intervention group
Group type: COMPARATOR
Intervention: Future Patient Telerehabilitation Program A
Number of subjects: 0
Study 34279241 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week remote group-mediated physical activity and dietary weight loss intervention followed by a 12-week maintenance period
Number of subjects: 30
Study 34279241 — intervention group
Group type: COMPARATOR
Intervention: Control condition (self-monitoring tools only)
Number of subjects: 30
Study 34279677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 230
Study 34279812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI assessment
Number of subjects: 0
Study 34280258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (BTK inhibitor)
Number of subjects: 90
Study 34280258 — intervention group
Group type: COMPARATOR
Intervention: Asparaginase (ASNase) therapy
Number of subjects: 90
Study 34280257 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1-TCB antibody
Number of subjects: 26
Study 34280257 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1-TCB combined with lenalidomide
Number of subjects: 26
Study 34280383 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsened depressive symptoms
Number of subjects: 8784
Study 34280383 — intervention group
Group type: COMPARATOR
Intervention: Stable depressive symptoms
Number of subjects: 8784
Study 34280383 — intervention group
Group type: COMPARATOR
Intervention: Improved depressive symptoms
Number of subjects: 8784
Study 34280383 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsened depressive symptoms (after controlling for confounders)
Number of subjects: 8784
Study 34280572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Pain Screening Tool (PPST)
Number of subjects: 109
Study 34280868 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath analysis using SESI-HRMS
Number of subjects: 149
Study 34281363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor Monotherapy
Number of subjects: 0
Study 34281363 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor with Aspirin
Number of subjects: 0
Study 34281606 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of Event Scale Revised score ≥ 33
Number of subjects: 107
Study 34281606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Component Scale score
Number of subjects: 107
Study 34281606 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Component Scale score
Number of subjects: 107
Study 34281607 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) searches
Number of subjects: 446
Study 34281607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewing upcoming clinic schedules
Number of subjects: 446
Study 34281607 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacting past trial participants
Number of subjects: 446
Study 34281607 — intervention group
Group type: COMPARATOR
Intervention: Non-use of EHR for recruitment
Number of subjects: 446
Study 34281614 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) for soil-transmitted helminths (STH)
Number of subjects: 3
Study 34281806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone dispensing training
Number of subjects: 72
Study 34281912 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2636771 (200 mg) plus enzalutamide (160 mg)
Number of subjects: 37
Study 34281912 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2636771 (300 mg) plus enzalutamide (160 mg)
Number of subjects: 37
Study 34281912 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2636771 (400 mg) plus enzalutamide (160 mg)
Number of subjects: 37
Study 34282038 — intervention group
Group type: EXPERIMENTAL
Intervention: FRED flow diverter
Number of subjects: 145
Study 34282069 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal sparing (FS) eyes
Number of subjects: 33
Study 34282069 — intervention group
Group type: COMPARATOR
Intervention: Non-foveal sparing (non-FS) eyes
Number of subjects: 33
Study 34282069 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected distance visual acuity
Number of subjects: 33
Study 34282069 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular pigment optical density measurements
Number of subjects: 33
Study 34282079 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient motivational enhancement therapy (4 sessions)
Number of subjects: 544
Study 34282079 — intervention group
Group type: COMPARATOR
Intervention: Outpatient motivational enhancement therapy followed by community reinforcement approach for seniors (8 sessions)
Number of subjects: 544
Study 34282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal Pain Survey shoulder subscale
Number of subjects: 35
Study 34282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampa Kinesiophobia Scale-11
Number of subjects: 35
Study 34282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale
Number of subjects: 35
Study 34282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire
Number of subjects: 35
Study 34282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Coping Inventory-42
Number of subjects: 35
Study 34282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Quality of Life Questionnaire
Number of subjects: 35
Study 34282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34282409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 1605
Study 34282496 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceased donor liver-derived natural killer (NK) cell infusion
Number of subjects: 18
Study 34282506 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic mesh (Phasix™)
Number of subjects: 84
Study 34282539 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time diagnostic tool using time-frequency analysis (TFA) of log files
Number of subjects: 173
Study 34282579 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGUS device for endoscopic septotomy
Number of subjects: 2
Study 34282646 — intervention group
Group type: EXPERIMENTAL
Intervention: rGV (R package for glycemic variability metrics)
Number of subjects: 0
Study 34282646 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 34282646 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose
Number of subjects: 0
Study 34282853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (various programs)
Number of subjects: 438
Study 34282853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (squats using a vibration platform)
Number of subjects: 438
Study 34282853 — intervention group
Group type: COMPARATOR
Intervention: Supervised upper limb exercise (SULP)
Number of subjects: 438
Study 34282853 — intervention group
Group type: COMPARATOR
Intervention: Multimodal exercise training
Number of subjects: 438
Study 34282853 — intervention group
Group type: COMPARATOR
Intervention: Multimodal exercise programs (7 weeks vs 14 weeks)
Number of subjects: 438
Study 34283023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet intervention containing IPV questions and a film to promote safety behaviors
Number of subjects: 10
Study 34283023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 10
Study 34283027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment and intervention (EMAI)
Number of subjects: 48
Study 34283027 — intervention group
Group type: COMPARATOR
Intervention: Control arm (EMA data submission only)
Number of subjects: 48
Study 34283029 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of urinary exosomal CA9 using transmission electron microscopy, flow cytometry, and reverse transcription-quantitative polymerase chain reaction.
Number of subjects: 100
Study 34283029 — intervention group
Group type: COMPARATOR
Intervention: Noncancer patients (control group) for comparison.
Number of subjects: 100
Study 34283213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 7413
Study 34283294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) regimen
Number of subjects: 246
Study 34283629 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (HSCT) after 5-aza pretreatment
Number of subjects: 190
Study 34283629 — intervention group
Group type: COMPARATOR
Intervention: Continuous 5-aza treatment
Number of subjects: 190
Study 34283704 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study 34283704 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening
Number of subjects: 0
Study 34284523 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-κB decoy injection into degenerated IVDs
Number of subjects: 0
Study 34284523 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-κB decoy injection
Number of subjects: 0
Study 34284599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) performed in 175 patients (51.6%); mechanical thrombectomy in 139 patients.
Number of subjects: 339
Study 34284599 — intervention group
Group type: COMPARATOR
Intervention: Medical management (control group).
Number of subjects: 339
Study 34284599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) group.
Number of subjects: 339
Study 34285010 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for data collection including personal profile, monthly event tracker, and patient-reported outcomes instruments.
Number of subjects: 2000
Study 34285010 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 2000
Study 34285010 — intervention group
Group type: EXPERIMENTAL
Intervention: Myasthenia Gravis Activities of Daily Living
Number of subjects: 2000
Study 34285010 — intervention group
Group type: EXPERIMENTAL
Intervention: Myasthenia Gravis Quality of Life 15-item revised scale
Number of subjects: 2000
Study 34285010 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 2000
Study 34285010 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index III
Number of subjects: 2000
Study 34285097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower LDL and statin use
Number of subjects: 5047
Study 34285097 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP levels 120-139 mmHg and DBP levels 80-89 mmHg
Number of subjects: 5047
Study 34285097 — intervention group
Group type: COMPARATOR
Intervention: Lower blood pressure levels
Number of subjects: 5047
Study 34285574 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 1699
Study 34285574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1699
Study 34285598 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 25 mg
Number of subjects: 12
Study 34285598 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg once daily (days 1-5) + Trazpiroben 25 mg post itraconazole on day 4
Number of subjects: 12
Study 34286103 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose rifampicin and adjunctive linezolid, with or without aspirin
Number of subjects: 0
Study 34286103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34286354 — intervention group
Group type: EXPERIMENTAL
Intervention: Best possible medication history (BPMH) by hospital pharmacist at inclusion and therapeutic drug monitoring
Number of subjects: 51
Study 34286354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions
Number of subjects: 51
Study 34286454 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.3 U/kg
Number of subjects: 0
Study 34286454 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.2 U/kg
Number of subjects: 0
Study 34286459 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-102 topical application once every 14 days (Cohort 1)
Number of subjects: 56
Study 34286459 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-102 topical application once every 21 days in conjunction with paring (Cohort 2)
Number of subjects: 56
Study 34286459 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessments for both cohorts
Number of subjects: 56
Study 34286513 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum soluble Sdc1 levels in active UC group
Number of subjects: 0
Study 34286513 — intervention group
Group type: COMPARATOR
Intervention: Serum soluble Sdc1 levels in inactive UC group
Number of subjects: 0
Study 34286513 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Sdc1 with severity of UC (Mayo score)
Number of subjects: 0
Study 34286513 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis of Sdc1 with endoscopic Mayo score ≥2
Number of subjects: 0
Study 34286513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff value of Sdc1
Number of subjects: 0
Study 34286513 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of biomarkers including CRP, hemoglobin, hematocrit, and Sdc1
Number of subjects: 0
Study 34286512 — intervention group
Group type: EXPERIMENTAL
Intervention: More home visits (5 studies, 2102 women)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: COMPARATOR
Intervention: Fewer home visits (2 studies, 862 women)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: EXPERIMENTAL
Intervention: More home visits (4 studies, 1365 infants)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: EXPERIMENTAL
Intervention: More home visits (3 studies, 960 women)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised care by midwives (1 study, 1295 women)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (3 studies, 2368 women)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (1 study, 513 women)
Number of subjects: 12080
Study 34286512 — intervention group
Group type: COMPARATOR
Intervention: Home visits vs. facility-based care (3 studies, 3257 women)
Number of subjects: 12080
Study 34286624 — intervention group
Group type: EXPERIMENTAL
Intervention: Family function, perceived support, and caregiver burden measured at four different time points over one year.
Number of subjects: 0
Study 34286638 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue with fermented wheat germ extract (FWGE) for at least 4 months
Number of subjects: 36
Study 34286638 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue
Number of subjects: 36
Study 34286886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy administration and dispensing of methadone for MMT (5-160 mg/day for 3 months)
Number of subjects: 20
Study 34286886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy administration and dispensing of methadone for MMT
Number of subjects: 20
Study 34287023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline; specific dosage and duration not available
Number of subjects: 0
Study 34287217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening using an oral fluid-based rapid test (OFT)
Number of subjects: 1907
Study 34287217 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with web-based data collection system
Number of subjects: 1907
Study 34287262 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing the time of day for taking endocrine therapy (tamoxifen and/or aromatase inhibitors)
Number of subjects: 0
Study 34287805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib (PARTRUVIX™; BeiGene Ltd.)
Number of subjects: 0
Study 34287942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg q2wks
Number of subjects: 212
Study 34288026 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of post-transplant cyclophosphamide
Number of subjects: 0
Study 34288026 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34288223 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe irritability group (n=46)
Number of subjects: 108
Study 34288223 — intervention group
Group type: COMPARATOR
Intervention: Healthy youths group (n=62)
Number of subjects: 108
Study 34288271 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (levodopa)
Number of subjects: 28
Study 34288271 — intervention group
Group type: COMPARATOR
Intervention: Subthalamic nucleus deep brain stimulation
Number of subjects: 28
Study 34288547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (PPI)
Number of subjects: 27
Study 34288547 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 27
Study 34288547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib oral solution
Number of subjects: 27
Study 34288547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 27
Study 34288560 — intervention group
Group type: EXPERIMENTAL
Intervention: Single crown/bridge rehabilitation
Number of subjects: 58
Study 34288560 — intervention group
Group type: COMPARATOR
Intervention: All-on-4 rehabilitation
Number of subjects: 58
Study 34288560 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients population
Number of subjects: 58
Study 34288738 — intervention group
Group type: EXPERIMENTAL
Intervention: AFFIRM questionnaire (33-item patient-reported outcome measure)
Number of subjects: 102
Study 34288738 — intervention group
Group type: EXPERIMENTAL
Intervention: AFFIRM-A
Number of subjects: 102
Study 34288738 — intervention group
Group type: EXPERIMENTAL
Intervention: AFFIRM-U
Number of subjects: 102
Study 34288738 — intervention group
Group type: EXPERIMENTAL
Intervention: AFFIRM questionnaire
Number of subjects: 102
Study 34288738 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported symptoms
Number of subjects: 102
Study 34289017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/d) and ulocuplumab (cycles 1 to 6, 4 weeks each)
Number of subjects: 13
Study 34289231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy
Number of subjects: 80
Study 34289231 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study 34289656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 (single dose) and oral prednisone (for at least 5 days) prior to chemoimmunotherapy
Number of subjects: 33
Study 34289656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab/prednisone prephase treatment
Number of subjects: 33
Study 34289656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prephase treatment
Number of subjects: 33
Study 34289815 — intervention group
Group type: EXPERIMENTAL
Intervention: HGS weakness (HGSw)
Number of subjects: 43
Study 34289815 — intervention group
Group type: COMPARATOR
Intervention: Non-HGS weakness (non-HGSw)
Number of subjects: 43
Study 34289829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac symptoms
Number of subjects: 1435
Study 34289829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care dependency
Number of subjects: 1435
Study 34289829 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 1435
Study 34289977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI)
Number of subjects: 237